Voriconazole treatment for less-common, emerging, or refractory fungal infections
Voriconazole treatment for less-common, emerging, or refractory fungal infections
复制标题
DOI：
10.1086/374557
复制
发表时间：
2003-05-01
影响因子：
11.8
通讯作者：
Johnson, E
中科院分区：
文献类型：
--
作者：
Perfect, JR;Marr, KA;Johnson, E
侵袭性真菌感染的治疗仍然不能令人满意。我们评价了伏立康唑作为273例难治性和不耐受性真菌感染患者的补救治疗以及作为28例未批准治疗的感染患者的主要治疗的疗效、耐受性和安全性。伏立康唑在50%的总体队列中具有令人满意的总体缓解;具体而言，在47%的感染对既往抗真菌治疗无效的患者和68%的感染未获得批准的抗真菌治疗的患者中观察到成功结局。在治疗失败的高风险人群中，伏立康唑对曲霉病、念珠菌病、隐球菌病、镰刀菌病和硬孢子虫病的有效率分别为43.7%、57.5%、38.9%、45.5%和30%。伏立康唑耐受性良好，治疗相关的治疗中断或剂量减少发生在
Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for